# HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

> **NCT05586074** · PHASE3 · RECRUITING · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 324 (estimated)

## Conditions studied

- Leukemia, Acute Myeloid (AML)

## Interventions

- **DRUG:** Clifutinib
- **DRUG:** LoDAC
- **DRUG:** Azacitidine
- **DRUG:** Decitabine
- **DRUG:** Ara-C±IDA
- **DRUG:** FLAG-IDA

## Key facts

- **NCT ID:** NCT05586074
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-03
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-05-30
- **Target enrollment:** 324 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05586074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05586074, "HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05586074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*